Page last updated: 2024-10-29

ketanserin and Parkinson Disease, Secondary

ketanserin has been researched along with Parkinson Disease, Secondary in 1 studies

Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, Y1
Huang, XF1
Deng, C1
Meyer, B1
Wu, A1
Yu, Y1
Ying, W1
Yang, GY1
Yenari, MA1
Wang, Q1

Other Studies

1 other study available for ketanserin and Parkinson Disease, Secondary

ArticleYear
Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats.
    Synapse (New York, N.Y.), 2010, Volume: 64, Issue:3

    Topics: Analysis of Variance; Animals; Autoradiography; Brain; Dopamine; Image Processing, Computer-Assisted

2010